Paradiso Angelo Virgilio, De Summa Simona, Silvestris Nicola, Tommasi Stefania, Tufaro Antonio, Larocca Angela Maria Vittoria, D'Addabbo Vincenzo, Raffaele Donata, Cafagna Vito, Garrisi Vito Michele, De Palma Giuseppe
Scientific Direction, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
Diagnostics (Basel). 2021 May 28;11(6):975. doi: 10.3390/diagnostics11060975.
Health-care workers (HCW) are at high risk for SARS-CoV-2 infection and, if asymptomatic, for transmitting the virus to fragile cancer patients. We monitored all asymptomatic HCWs of a cancer institute (94% of all employees agreed to enter the study) with the rapid serological test, VivaDiag, identifying SARS-CoV-2 associated-IgM/IgG. The tests were performed at time 0 ( = 606) and after 14 days ( = 393). Overall, the VivaDiag results of nine HCWs (1.5%) were positive, with one confirmed to be SARS-CoV-2-positive after oropharyngeal swab testing by RT-PCR. At time 0, all nine cases showed IgM expression while IgG was detected in only one. After 14 days, IgM persisted in all the cases, while IgG became evident in four. A chemiluminescence immunoassay (CLIA) confirmed IgM positivity in 5/13 VivaDiag positive cases and IgG positivity in 4/5 VivaDiag positive cases. Our study suggests that the VivaDiag test can be of help in identifying SARS-CoV-2 infected people in cohorts of subjects with a high prevalence.
医护人员感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的风险很高，而且如果无症状，还会将病毒传播给脆弱的癌症患者。我们使用快速血清学检测VivaDiag监测了一家癌症研究所的所有无症状医护人员（94%的员工同意参与研究），以识别与SARS-CoV-2相关的IgM/IgG。检测在0时刻（n = 606）和14天后（n = 393）进行。总体而言，9名医护人员（1.5%）的VivaDiag检测结果呈阳性，其中1人经逆转录聚合酶链反应（RT-PCR）进行咽拭子检测后被确认为SARS-CoV-2阳性。在0时刻，所有9例病例均显示IgM表达，而仅1例检测到IgG。14天后，所有病例中IgM持续存在，而4例出现了明显的IgG。化学发光免疫分析（CLIA）证实，13例VivaDiag检测阳性病例中有5例IgM呈阳性，5例VivaDiag检测阳性病例中有4例IgG呈阳性。我们的研究表明，VivaDiag检测有助于在高患病率人群中识别感染SARS-CoV-2的人。
